Rhapsido / remibrutinib for chronic Spontaneous Urticaria as of February 2026 MARA Rating Company February 28, 2026 Read More »
Ekterly / sebetralstat for treating Acute Attacks of Hereditary Angioedema as of February 2026 MARA Rating Company February 28, 2026 Read More »
Sepiapterin sephience for treating Hyperphenylalaninemia in Phenylketonuria as of February 2026 MARA Rating Company February 28, 2026 Read More »
Sevabertinib for treating HER2 Mutant NSCLC as of February 2026 MARA Rating Company February 28, 2026 Read More »
Adquey / difamilast for mild-to-Moderate Atopic Dermatitis in US, EU5, and Japan as of February 2026 MARA Rating Company February 28, 2026 Read More »
Dawnzera / donidalorsen for prevention of Hereditary Angioedema Attacks as of February 2026 MARA Rating Company February 28, 2026 Read More »
Forzinity / elamipretide for barth Syndrome as of February 2026 MARA Rating Company February 28, 2026 Read More »
Lynkuet / elinzanetant for menopausal Vasomotor Symptoms as of February 2026 MARA Rating Company February 28, 2026 Read More »
Etripamil for acute PSVT episode termination as of February 2026 MARA Rating Company February 28, 2026 Read More »
Qfitlia / fitusiran for preventing bleeding episodes in hemophilia A or B as of February 2026 MARA Rating Company February 28, 2026 Read More »